Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Two new studies have been published that further focus attention on how the renin–angiotensin ...

The renin-angiotensin system (RAS) remains a cornerstone of cardiovascular and renal physiology, orchestrating vital aspects of blood pressure regulation and fluid-electrolyte balance. At the heart of ...

A new viewpoint article published in the journal JAMA Network in April 2020 deals with the use of a widely used category of cardiovascular medications in COVID-19 patients with hypertension, diabetes, ...

ACE inhibitors and angiotensin-receptor blockers have been found to effectively slow progression of kidney disease. It has been theorized that dual blockade of the renin-angiotensin-aldosterone system ...

New Orleans, La. (March 27, 2007) -- A combination of two medicines that act against the effects of the enzyme renin are more effective in lowering blood pressure than either of the medicines alone, ...

Initial evidence of the existence of renin, which is an angiotensinogenase enzyme secreted by the kidney, was presented to the medical community more than 100 years ago. Nevertheless, the significance ...

A randomized trial tested the potential additive benefit of active vitamin D in reducing proteinuria in patients with IgA nephropathy.

[Updated]-- The European Medicines Agency said last week that it was initiating a review of the combined use of agents that block the renin-angiotensin system (RAS). The three classes of RAS-blocking ...

The FDA approved aliskiren, the first hypertension treatment that inhibits renin. Aliskiren (Tekturna, Novartis) is also the first, new type of hypertension drug approved by the FDA in more than a ...

Approximately one in five eligible patients hospitalized for ACS do not receive guideline-recommended ACE inhibitor or angiotensin receptor blocker therapies. Guidelines from the American College of ...